Form 4: Leap Therapeutics Executive Exercises Warrants, Acquires Shares

Augustine Lawlor, Chief Operating Officer of Leap Therapeutics, indirectly acquired 2,136 shares of common stock through the exercise of a warrant by Nine Capital Partners, LLC.

Summary

• Augustine Lawlor, the Chief Operating Officer of Leap Therapeutics, has reported a change in beneficial ownership of the company's stock.
• On November 13, 2024, Nine Capital Partners, LLC, of which Lawlor is a managing member, exercised a warrant to purchase 2,136 shares of Leap Therapeutics common stock at $2.82 per share.
• Lawlor may be deemed to have beneficial ownership of these shares due to his position at Nine Capital Partners, although he disclaims direct ownership except for his proportionate pecuniary interest.
• Lawlor also has indirect beneficial ownership of 414,480 shares held by HealthCare Ventures IX, L.P. and 261,840 shares held by the HCV VIII Trust.
• Lawlor disclaims beneficial ownership of these shares except for his proportionate pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a factual report of a transaction.

Industry Context

This is a routine filing related to insider transactions and is common in the biotechnology industry where stock options and warrants are often part of executive compensation packages.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, including biotechnology companies like Leap Therapeutics.
• The transaction is typical of executive compensation and investment structures in the biotech sector, where warrants and stock options are frequently used.
• Similar filings can be seen from executives at companies like Amgen, Gilead, and Biogen, which also use stock-based compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a small number of shares relative to the total outstanding shares.
• The transaction is a routine part of executive compensation and does not indicate any significant change in the company's operations or financial health.

Key Dates

Keywords

beneficial ownership, warrant exercise, common stock, Leap Therapeutics, insider trading, Nine Capital Partners, HealthCare Ventures